X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
GUBamy (GUB014295) is a long-acting amylin agonist for once weekly subcutaneous administration. It is under phase 1 clinical development for the potential treatment of obesity.
Lead Product(s): GUB014295
Therapeutic Area: Nutrition and Weight Loss Product Name: GUBamy
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2023
Details:
The net proceeds are expected to be used for geographic expansion of the contract research activities, continued development of the drug candidate pipeline including amylin for the treatment of obesity, technological solutions and proprietary platforms as well as acquisitions.
Lead Product(s): Amylin
Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Skandinaviska Enskilda Banken
Deal Size: $71.6 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 06, 2023
Details:
The collaboration will combine Gubra’s unique peptide drug discovery capabilities and use of advanced technologies with Bayer AG’s expertise in development of innovative medicines.
Lead Product(s): Undisclosed
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Bayer AG
Deal Size: $253.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration September 20, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
